About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Asthma Clinical Trials in New York | 435 Studies | Clareo Health

Clinical Trials AsthmaNew York

Asthma Clinical Trials in New York

Find 435 clinical trials for asthma near New York, New York. Connect with research centers in your area.

All Asthma trials nationwide All trials in New York

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 361-380 of 435 trials

COMPLETEDPhase 4< 1 mile

The Study of Soy Isoflavones in Asthma

NCT01052116

The trial is designed to study the effects of soy supplements on asthma control.

American Lung Association Asthma Clinical Research Centers386 participantsStarted Mar 2010

Tucson, Arizona, United States • San Diego, California, United States • Denver, Colorado, United States +15 more locations

COMPLETEDPhase 4< 1 mile

Study of Asthma and Nasal Steroids

NCT01118312

The trial will study the effectiveness of nasal steroids for the treatment of chronic rhinitis and/or sinusitis on asthma control.

AsthmaRhinitisSinusitis

JHSPH Center for Clinical Trials388 participantsStarted Sep 2010

Tucson, Arizona, United States • San Diego, California, United States • Denver, Colorado, United States +16 more locations

Asthma Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

COMPLETED< 1 mile

The Role of Epigenetics in Inner City Asthma

NCT01382836

As part of ongoing efforts to determine the causes of asthma and the progression of the disease, this study will gather data to explore the interaction of genetic and environmental factors in the cause and severity of asthma in inner city children.

National Institute of Allergy and Infectious Diseases (NIAID)200 participantsStarted Jan 2011

Denver, Colorado, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +3 more locations

COMPLETED< 1 mile

The Impact of Fellow-performed Cardiopulmonary Ultrasound Exams

NCT02186197

Shock and respiratory failure are common reasons for admission to the intensive care unit (ICU) at our institution. The various causes of acute shock and respiratory failure are traditionally assessed with the use of history, physical examination, chest x-ray, EKG and laboratory studies. Unfortunately, much of this clinical information is either insensitive or non-specific. 1 Critical care ultrasound (CCUS) is a rapid and non-invasive tool, which has been shown to be useful in the intensive care unit to assist in the diagnosis and management of patients in shock or respiratory failure.2 The investigators hypothesize that the trained fellow's interpretation of critical care ultrasound images will be accurate when compared to experts and that ultrasounds will change diagnosis and management of the patient in shock and respiratory failure.

ShockRespiratory Failure

Beth Israel Medical Center112 participantsStarted Jul 2014

New York, New York, United States

COMPLETEDPhase 2< 1 mile

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

NCT00879606

This is a prospective, randomized (1:1), double-blind, multi-center, Phase II clinical study to test the safety and efficacy of a recombinant chimeric anti-tissue factor antibody (ALT-836) versus placebo in patients with sepsis and acute lung injury/acute respiratory distress syndrome (ALI/ARDS). This study was divided into two parts and the first part of the study has been completed. In the first part of the study, sixty patients were randomized at a 1:1 ratio to receive one dose of the study drug or placebo. In the second part of the study, ninety patients will be randomized at a 1:1 ratio to receive a multi-dose treatment regimen of single doses every 72 hours up to a maximum of 4 doses of the study drug or placebo, provided there are no safety concerns.

SepsisAcute Lung InjuryAcute Respiratory Distress Syndrome

Altor BioScience150 participantsStarted Apr 2009

Los Angeles, California, United States • Sacramento, California, United States • Stanford, California, United States +17 more locations

COMPLETEDPhase 2< 1 mile

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

NCT01545440

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an inhaled corticosteroid and a second controller medication. Patients will be randomized in a 1:1:1:1 ratio to receive double-blind treatment with subcutaneous lebrikizumab ("highest", "middle", "lowest" dose) or placebo every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is up to 104 weeks. There will be a safety follow-up of 24 weeks after the last dose of study drug for all patients.

Genentech, Inc.258 participantsStarted Mar 2012

Pell City, Alabama, United States • Scottsdale, Arizona, United States • Scottsdale, Arizona, United States +68 more locations

COMPLETEDPhase 3< 1 mile

Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV)

NCT00433212

The machines and oxygen used to help very premature babies breathe can have side-effects, such as bronchopulmonary dysplasia (BPD). Infants with BPD get more complications (a higher death rate, a longer time in intensive care and on assisted ventilation, more hospital readmissions in the first year of life, and more learning problems) than infants who do not develop BPD. Doctors try to remove the tube in the wind-pipe that links the baby to the breathing machine as soon as possible. However, small babies get tired, and still require help to breathe. One of the standard and common techniques to help them breathe without a tube in the wind-pipe is to use simple pressure support, nasal continuous positive airway pressure or nCPAP. This supports breathing a little, but it is often not enough to prevent the need to go back on the breathing machine. Nasal intermittent positive pressure ventilation (NIPPV) is similar to nCPAP, but also gives some breaths, or extra support, to babies through a small tube in the nose. NIPPV is safe and effective, and already in use as an alternate "standard" therapy. The main research question: After being weaned from the breathing machine, is NIPPV better than nCPAP in preventing BPD in premature babies weighing 999 grams or less at birth?

Respiratory Insufficiency of Prematurity

McMaster University1,011 participantsStarted Apr 2007

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +32 more locations

TERMINATEDNA8.9 miles

The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs

NCT01003730

This research is being done to determine if there is a way the investigators can improve the techniques that they use to assist patients with their breathing during surgery. The majority of surgeries require patients to concurrently undergo general anesthesia. This usually includes a breathing tube and a machine that breathes for the patient during the duration of the surgery. The doctors would like to investigate the effects of this type of anesthesia to healthy adult patients and whether they can improve the way they give general anesthesia to patients. The investigators plan to ask approximately 200 patients to participate. If the patients decide to participate in the study,some additions will be made to the standard anesthetic care they receive. The patients will additionally be monitored for adequate oxygenation in their blood as well as level of inflammation in their blood and lungs. The patients' breathing tube will be bathed with warm normal saline and suctioned twice during the operation. When these procedures are done the patients will be asleep and not be aware of what is happening.

Acute Respiratory Distress Syndrome

University of Medicine and Dentistry of New Jersey1 participantsStarted Mar 2009

Newark, New Jersey, United States

COMPLETEDPhase 39.1 miles

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406

To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED patients with refractory acute asthma helps improve forced expiratory volume at one second (FEV1) and decrease the need for hospitalization.

Northwell Health95 participantsStarted Sep 2007

East Meadow, New York, United States • Queens, New York, United States • The Bronx, New York, United States

COMPLETEDPhase 29.1 miles

Study of Pulmozyme to Treat Severe Asthma Episodes

NCT00169962

Even with current standard ED treatments 20-25% of patients presenting to the ED with an acute asthma episode will still require hospitalization. For patients unresponsive to beta-agonists the admit rates will be higher. Of those well enough to be discharged from the ED nearly 30% will relapse within one month. More than 5,000 patients with asthma still die each year in the USA. For patients who do not respond to beta-agonists, there are relatively few treatment options for rapid improvement of symptoms and pulmonary function. Presumably, mucous secretion and plugging play an important role in the pathogenesis of severe asthma unresponsive to beta-agonists. The use of agents to promote clearance of intra-luminal secretions and mucous plugs may represent an important advance in the management of acutely ill asthmatics, both to hasten recovery and prevent deterioration in the acute care setting and to prevent relapse after discharge from the ED. OBJECTIVES 2.1 Study Hypothesis: rhDNAse can be safely used in patients presenting to the Emergency Department with acute moderate-severe asthma who do not have adequate responses to beta-agonists Project Specific Aim: This is a pilot study to determine the safety of three different doses of pulmozyme® (2.5mg, 5.0mg and 7.5mg) in patients presenting to the ED with acute asthma. In addition to safety trends for improvement in pulmonary function and clinical outcomes will be monitored and data analyzed. Based on the safety profile and observable responses to treatment, this information may be used to develop larger trials to determine the efficacy and dosing strategy for treating acutely ill asthmatics with rhDNAse.

Northwell Health51 participantsStarted Jan 2004

Queens, New York, United States

TERMINATEDPhase 319 miles

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009

This is a one-year study to look at the safety of a dry powder inhaler with albuterol. After a one-week run in, for the first 3 months subjects will use an inhaler with either albuterol or a dummy drug at regular times four times a day. Then for the last nine months of the study, all subjects will be given the albuterol dry powder inhaler and will use it only when needed to help with breathing problems. Subjects will need to keep a daily diary (both paper and electronic) throughout the study recording any inhaler use and health problems. There will be visits to the study doctor about once a month for a year. This study is intended to show that the albuterol dry powder inhaler works well and is safe for use over a long period of time.

Teva Branded Pharmaceutical Products R&D, Inc.331 participantsStarted Oct 2010

Scottsdale, Arizona, United States • Los Angeles, California, United States • San Diego, California, United States +27 more locations

COMPLETEDPhase 319 miles

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

NCT01277523

The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma. The primary objective of the trial is to demonstrate superiority of tiotropium (5 mcg and possibly 2.5 mcg once daily in the evening) over placebo with regard to the primary pulmonary function endpoint after 12 weeks of treatment. Secondary objectives are to evaluate efficacy of tiotropium with regard to other endpoints, and to evaluate the safety of tiotropium, compared to placebo, as add-on controller therapy on top of usual care in this patient population.

Boehringer Ingelheim392 participantsStarted Jan 2011

Stockton, California, United States • Normal, Illinois, United States • Baltimore, Maryland, United States +66 more locations

TERMINATEDPhase 370 miles

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

NCT00005774

Mechanical ventilation (MV) of preterm infants with respiratory distress syndrome (RDS) is associated with lung injury and nosocomial infection. Moderately premature infants with mild respiratory distress do not routinely receive artificial surfactant early in their course of treatment. This multi-center, randomized trial tested whether early surfactant therapy and nasal continuous positive airway pressure (CPAP) in infants 1,250-2,000g with RDS reduced mechanical ventilation usage without added complications. Infants with mild to moderate respiratory distress syndrome were enrolled in the trial and given either early administration of surfactant followed by extubation within 30 minutes and the use of CPAP, or standard practice (surfactant according to current center practice, only after initiation of mechanical ventilation), to see whether the experimental method would reduce the need for subsequent mechanical ventilation.

Infant, NewbornRespiratory Distress SyndromeRespiratory Insufficiency

NICHD Neonatal Research Network61 participantsStarted May 2000

Birmingham, Alabama, United States • Palo Alto, California, United States • New Haven, Connecticut, United States +10 more locations

COMPLETEDPhase 372 miles

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

NCT01747629

The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.

Teva Branded Pharmaceutical Products R&D, Inc.160 participantsStarted Dec 2012

Costa Mesa, California, United States • Encinitas, California, United States • Huntington Beach, California, United States +32 more locations

TERMINATEDPhase 380 miles

The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial

NCT01506401

What is the effect of early high frequency oscillation (HFO) versus a lung-protective conventional ventilation (CV) strategy (using HFO only as rescue therapy), on all-cause hospital mortality among patients with severe early acute respiratory distress syndrome (ARDS)?

Acute Respiratory Distress Syndrome (ARDS)

Canadian Critical Care Trials Group548 participantsStarted Jun 2009

Denver, Colorado, United States • Orlando, Florida, United States • Ann Arbor, Michigan, United States +35 more locations

TERMINATEDPhase 3151 miles

Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

NCT01947946

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on medium doses of ICS-LABA.

AstraZeneca13 participantsStarted Nov 2013

Birmingham, Alabama, United States • Glendale, Arizona, United States • San Jose, California, United States +44 more locations

COMPLETEDPhase 3170 miles

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

NCT01857323

This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD. The purpose of this study is to evaluate the functionality, reliability, and accuracy of the Albuterol Spiromax inhaler integrated dose counter in a clinical setting.

AsthmaChronic Obstructive Pulmonary Disease (COPD)

Teva Branded Pharmaceutical Products R&D, Inc.317 participantsStarted May 2013

Phoenix, Arizona, United States • Costa Mesa, California, United States • Huntington Beach, California, United States +27 more locations

COMPLETEDNA190 miles

PROVHILO:Protective Ventilation During General Anesthesia for Open Abdominal Surgery

NCT01441791

The purpose of this international, multicentre, double-blinded randomized controlled trial is to determine if the "open lung approach" providing recruitment maneuvers and PEEP(Positive End Expiratory Pressure) during general anesthesia reduces atelectasis formation and improves respiratory function in the immediate post-operative period after major abdominal surgery. Participating centres throughout the world will include a total of 900 adult patients undergoing general anesthesia for open abdominal surgery with high or intermediate risk for post-operative pulmonary complications. Patients are randomized and intra-operatively ventilated with either a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers) or a conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers). Patients will be assessed on the first 5 post-operative days, on day of discharge and on day 90 post-operative. Primary endpoint is any post-operative pulmonary complication (see below). Secondary endpoints are post-operative extra-pulmonary complications, intra-operative mechanical ventilation related complications, unscheduled ICU (Intensive Care Unit) (re-) admission, and length of hospital stay.

Postoperative Respiratory Complications

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)900 participantsStarted Feb 2011

Boston, Massachusetts, United States • Rochester, New York, United States • Vienna, Austria +27 more locations

COMPLETEDPhase 2327 miles

Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma

NCT01609478

To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.

Novartis Pharmaceuticals335 participantsStarted Aug 2012

Rousse, Bulgaria, Bulgaria • Sofia, Bulgaria, Bulgaria • Sofia, Bulgaria, Bulgaria +93 more locations

COMPLETEDPhase 2631 miles

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113

The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with persistent asthma on top of inhaled corticosteroid (ICS) treatment.

Boehringer Ingelheim102 participantsStarted Jul 2012

Columbia, Missouri, United States • Oklahoma City, Oklahoma, United States • Charleston, South Carolina, United States +30 more locations

PreviousPage 19 of 22Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia